A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

Lei Li

Status: Completed

Conditions: Epithelial Ovarian Cancer; Homologous Recombination Genes; Homologous Recombination Deficiency; BRCA2 Mutation; Chinese; BRCA1 Mutation; Prognosis

Treatments: Genetic: Evaluation of homologous recombination deficiency score

Study type: Observational

Funder types: Other

Identifiers

NCT04651920

EOC-HRD2

Details and patient eligibility

About

The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients is little known. This study would recruit 400 Chinese EOC patients with known targeted gene mutations via a multi-panel testing of 27 genes, including BRCA1/BRCA2. All patients accept evaluation of HRD model, which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST). The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients, and a potential explanation of platinum-resistance in such population.

Enrollment: 240 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged 18 years or older
• Pathological confirmation of epithelial ovarian cancer
• With available tumor tissues
• Given consents to participate the study

Exclusion criteria

• Not meeting all of the inclusion criteria

Trial design

240 participants in 2 patient groups

Epithelial ovarian cancer patients sensitive to platinum based chemotherapy

Treatment:

Genetic: Evaluation of homologous recombination deficiency score

Epithelial ovarian cancer patients resistant to platinum based chemotherapy

Treatment:

Genetic: Evaluation of homologous recombination deficiency score